TY  - JOUR
AU  - Calleja-Conde, Javier
AU  - Echeverry-Alzate, Victor
AU  - Giné, Elena
AU  - Bühler, Kora-Mareen
AU  - Nadal, Roser
AU  - Maldonado, Rafael
AU  - Rodríguez de Fonseca, Fernando
AU  - Gual, Antoni
AU  - López-Moreno, Jose Antonio
PY  - 2016
DO  - 10.1111/bph.13526
UR  - http://hdl.handle.net/10668/10134
T2  - British journal of pharmacology
AB  - The opioid antagonist nalmefene (selincro®) was approved for alcohol-related disorders by the European Medicines Agency in 2013. However, there have been no studies regarding the effectiveness of nalmefene when alcohol is used in combination with...
LA  - en
KW  - Alcohol Drinking
KW  - Animals
KW  - Cocaine
KW  - Dose-Response Relationship, Drug
KW  - Drug Interactions
KW  - Ethanol
KW  - Gene Expression Regulation, Enzymologic
KW  - Histone Deacetylases
KW  - Male
KW  - Naltrexone
KW  - Rats
KW  - Rats, Wistar
KW  - Structure-Activity Relationship
TI  - Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood.
TY  - research article
VL  - 173
ER  -